CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB0440 : LC-2/ad]

1780 Kataoka H, Itoh H, Seguchi K, Koono M Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing α1-anititrypsin In Vitro Acta Pathologica Japonica 1993 43:566-573 PubMed ID: 8291444 DOI: 10.1111/j.1440-1827.1993.tb03232.x

Top

User's Publication

21740 Shiba-Ishii A, Isagawa T, Shiozawa T, Mato N, Nakagawa T, Takada Y, Hirai K, Hong J, Saitoh A, Takeda N, Niki T, Murakami Y, Matsubara D. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. Biochim Biophys Acta Mol Basis Dis 2024 167249 PubMed ID: 38768929 DOI: 10.1016/j.bbadis.2024.167249

21413 Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nat Cancer 2023 4(9):1345-1361 PubMed ID: 37743366 DOI: 10.1038/s43018-023-00630-y

17596 Hirai S, Idogawa M, Sumi T, Yamaguchi M, Niki T, Sakuma Y. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells Biochem Biophys Res Commun 2022 630:24-29 PubMed ID: 36126466 DOI: 10.1016/j.bbrc.2022.09.039

20933 Suphakhong K, Terashima M, Wanna-Udom S, Takatsuka R, Ishimura A, Takino T, Suzuki T. m6A RNA methylation regulates the transcription factors JUN and JUNB in TGF-β-induced epithelial-mesenchymal transition of lung cancer cells. J Biol Chem 2022 298(11):102554 PubMed ID: 36183833 DOI: 10.1016/j.jbc.2022.102554

13332 Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K. Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer. Oncol Rep 2021 PubMed ID: 33155667 DOI: 10.3892/or.2020.7839

20104 Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y. Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. Cancer Med 2021 PubMed ID: 33826244 DOI: 10.1002/cam4.3852

20304 Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K. Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. Lung Cancer 2021 158:115-125 PubMed ID: 34157583 DOI: 10.1016/j.lungcan.2021.06.011

12021 Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M, Tsukahara T, Suzuki T. The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem. Biophys. Res. Commun. 2020 PubMed ID: 31982139 DOI: 10.1016/j.bbrc.2020.01.042

12063 Kuchitsu Y, Nagashio R, Igawa S, Kusuhara S, Tsuchiya B, Ichinoe M, Satoh Y, Naoki K, Murakumo Y, Saegusa M, Sato Y. TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma. Biomed. Res. 2020 PubMed ID: 32092740 DOI: 10.2220/biomedres.41.53

13900 Fujimura T, Furugaki K, Harada N, Yoshimura Y. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells Cancer Biol Ther 2020 21(9):863-870 PubMed ID: 32835580 DOI: 10.1080/15384047.2020.1806643

14832 Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y. Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines Arch Virol 2020 165(1):207-214 PubMed ID: 31776677 DOI: 10.1007/s00705-019-04474-9

11833 Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, Kusuhara S, Igawa S, Shiomi K, Goshima N, Murakumo Y, Saegusa M, Satoh Y, Masuda N, Naoki K. Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma. Thorac Cancer 2019 PubMed ID: 31583841 DOI: 10.1111/1759-7714.13200

11040 Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion BMC Cancer 2019 19(1):301 PubMed ID: 30943926 DOI: 10.1186/s12885-019-5527-2

12502 Hagiuda D, Nagashio R, Ichinoe M, Tsuchiya B, Igawa S, Naoki K, Satoh Y, Murakumo Y, Saegusa M, Sato Y. Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma Biomed Res 2019 40(1):17-27 PubMed ID: 30787260 DOI: 10.2220/biomedres.40.17

11149 Shimizu K, Okita R, Saisho S, Maeda AI, Nojima Y, Nakata M. Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. Anticancer Res. 2018 38(8):4637-4644 PubMed ID: 30061230 DOI: 10.21873/anticanres.12768

11223 Terashima M, Ishimura A, Wanna-Udom S, Suzuki T. MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells. J. Biol. Chem. 2018 PubMed ID: 30262664 DOI: 10.1074/jbc.RA118.004006

4183 Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. Oncoimmunology 2018 PubMed ID: 30510853 DOI: 10.1080/2162402X.2018.1466771

9949 Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. Yonsei Med. J. 2017 58:9-18 PubMed ID: 27873490 DOI: 10.3349/ymj.2017.58.1.9

9950 Terashima M, Tange S, Ishimura A, Suzuki T. MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines. J. Biol. Chem. 2017 292:82-99 PubMed ID: 27852821 DOI: 10.1074/jbc.M116.750950

10280 Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncol. Rep. 2017 37:3261-3269 PubMed ID: 28440492 DOI: 10.3892/or.2017.5594

10408 Terashima M, Ishimura A, Wanna-Udom S, Suzuki T. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells. Biochem. Biophys. Res. Commun. 2017 490:1407-1413 PubMed ID: 28698146 DOI: 10.1016/j.bbrc.2017.07.048

10464 Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. J Mol Diagn 2017 19:682-696 PubMed ID: 28802831 DOI: 10.1016/j.jmoldx.2017.05.006

10922 Shigeaki Umeda et al Loss of IL-24 expression facilitates invasion in lung adenocarcinoma Int J Clin Exp Pathol 2017 10:173-185

14222 Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T. Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC Mol Cancer Res 2017 15(10):1354-1365 PubMed ID: 28698358 DOI: 10.1158/1541-7786.MCR-17-0191

14232 Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease Sci Rep 2017 7(1):10735 PubMed ID: 28878234 DOI: 10.1038/s41598-017-11255-4

14355 Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer Cancer Immunol Immunother 2017 66(7):865-876 PubMed ID: 28341875 DOI: 10.1007/s00262-017-1986-y

9522 Nishijima N, Seike M, Soeno C, Chiba M, Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K, Gemma A. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. Int. J. Oncol. 2016 48:937-44 PubMed ID: 26783187 DOI: 10.3892/ijo.2016.3331

12967 Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer Cancer Immunol Immunother 2016 65(5):499-509. PubMed ID: 26940474 DOI: 10.1007/s00262-016-1814-9

13983 Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y. Loss of YAP1 defines neuroendocrine differentiation of lung tumors Cancer Sci 2016 107(10):1527-1538 PubMed ID: 27418196 DOI: 10.1111/cas.13013

15849 Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients Clin Cancer Res 2016 22(4):915-22 PubMed ID: 26459174 DOI: 10.1158/1078-0432.CCR-15-1627-T

16655 Okudela K, Mitsui H, Woo T, Kojima Y, Matsumura M, Arai H, Suzuki T, Umeda S, Tateishi Y, Saito Y, Tajiri M, Masuda M, Kameda Y, Ohashi K. Expression of tropomyosins in lung cancer - a potential role in carcinogenesis and its utility in a histopathological diagnosis Histol Histopathol 2016 31(8):857-66 PubMed ID: 26750107 DOI: 10.14670/HH-11-721

7452 Liu G, Wu Q, Liu G, Song X, Zhang J. Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans. Cancer Cell Int. 2015 15:18 PubMed ID: 25745359 DOI: 10.1186/s12935-014-0154-0

13810 Chen S, Huang L, Sun K, Wu D, Li M, Li M, Zhong B, Chen M, Zhang S. Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis PLoS One 2015 10(5):e0125480 PubMed ID: 25974088 DOI: 10.1371/journal.pone.0125480

14286 Katono K, Sato Y, Jiang SX, Kobayashi M, Nagashio R, Ryuge S, Fukuda E, Goshima N, Satoh Y, Saegusa M, Masuda N. Prognostic significance of MYH9 expression in resected non-small cell lung cancer PLoS One 2015 10(3):e0121460 PubMed ID: 25826333 DOI: 10.1371/journal.pone.0121460

14314 Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells PLoS One 2015 10(10):e0139809 PubMed ID: 26439264 DOI: 10.1371/journal.pone.0139809

15025 Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment Genome Biol 2015 16(1):66 PubMed ID: 25887790 DOI: 10.1186/s13059-015-0636-y

15117 Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, Kubota K, Gemma A. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer Mol Cancer Ther 2015 14(11):2433-40 PubMed ID: 26351321 DOI: 10.1158/1535-7163.MCT-15-0050

15123 Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma Mol Cancer Ther 2015 14(10):2238-48 PubMed ID: 26208525 DOI: 10.1158/1535-7163.MCT-15-0350

15182 Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, Masuda N, Sato Y. S100A16 is a Prognostic Marker for Lung Adenocarcinomas Asian Pac J Cancer Prev 2015 16(16):7039-44 PubMed ID: 26514487 DOI: 10.7314/apjcp.2015.16.16.7039

15456 Yanagita K, Nagashio R, Ryuge S, Katono K, Jiang SX, Tsuchiya B, Nakashima H, Fukuda E, Goshima N, Saegusa M, Satoh Y, Masuda N, Sato Y. Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma Asian Pac J Cancer Prev 2015 16(17):7959-65 PubMed ID: 26625826 DOI: 10.7314/apjcp.2015.16.17.7959

4866 Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther 2014 13(12):2910-8 PubMed ID: 25349307 DOI: 10.1158/1535-7163.MCT-14-0274

15845 Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells Mol Cancer Ther 2014 13(2):444-53 PubMed ID: 24258346 DOI: 10.1158/1535-7163.MCT-13-0448

16607 Okudela K, Suzuki T, Umeda S, Tateishi Y, Mitsui H, Miyagi Y, Ohashi K. A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: potential involvement of miR-31 in lung carcinogenesis Oncol Rep 2014 32(4):1374-84 PubMed ID: 25050641 DOI: 10.3892/or.2014.3339

7714 Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2012 118:1599-606 PubMed ID: 21837672 DOI: 10.1002/cncr.26441

14287 Kobayashi M, Matsumoto T, Ryuge S, Yanagita K, Nagashio R, Kawakami Y, Goshima N, Jiang SX, Saegusa M, Iyoda A, Satoh Y, Masuda N, Sato Y. CAXII Is a sero-diagnostic marker for lung cancer PLoS One 2012 7(3):e33952 PubMed ID: 22439015 DOI: 10.1371/journal.pone.0033952

16490 Shiba-Ishii A, Noguchi M. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma Am J Pathol 2012 180(4):1653-62 PubMed ID: 22310466 DOI: 10.1016/j.ajpath.2011.12.014

16147 Kageyama T, Nagashio R, Ryuge S, Matsumoto T, Iyoda A, Satoh Y, Masuda N, Jiang SX, Saegusa M, Sato Y. HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer Asian Pac J Cancer Prev 2011 12(12):3457-63 PubMed ID: 22471497

16488 Shiba-Ishii A, Kano J, Morishita Y, Sato Y, Minami Y, Noguchi M. High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma Int J Cancer 2011 129(10):2445-53 PubMed ID: 21207417 DOI: 10.1002/ijc.25907

16553 Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer J Transl Med 2011 9:191 PubMed ID: 22053850 DOI: 10.1186/1479-5876-9-191

15847 Mizutani H, Okano T, Minegishi Y, Matsuda K, Sudoh J, Kitamura K, Noro R, Soeno C, Yoshimura A, Seike M, Gemma A. HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner Oncol Lett 2010 1(6):1011-1016 PubMed ID: 22870103 DOI: 10.3892/ol.2010.190

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

2481 Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, Mitsui H, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Takahashi T, Sugimura H, Kitamura H. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol 2009 175(2):867-81 PubMed ID: 19608870 DOI: 10.2353/ajpath.2009.080489

12769 Okudela K, Yazawa T, Ishii J, Woo T, Mitsui H, Bunai T, Sakaeda M, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Sugimura H, Kitamura H. Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis Am J Pathol 2009 175(6):2646-56 PubMed ID: 19893046 DOI: 10.2353/ajpath.2009.080571

3580 Ito T, Maki N, Hazeki O, Sasaki K, Nekooki M. Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines. Cell Biol Int 2007 31(12):1518-24 PubMed ID: 17719804 DOI: 10.1016/j.cellbi.2007.06.017

17469 Takiguchi Y, Miyamoto T, Nagao K, Kuriyama T. Assessment of the homogeneous efficacy of carbon ions in the spread-out Bragg peak for human lung cancer cell lines Radiat Med 2007 25(6):272-7 PubMed ID: 17634880 DOI: 10.1007/s11604-007-0134-6

3061 Nagai, Yoshiaki, Miyazawa, Hitoshi, Tanaka, Tomoaki, Udagawa, Kiyoshi, Kato, Motoyasu, Fukuyama, Shunichiro, Yokote, Akemi, Kobayashi, Kunihiko, Kanazawa, Minoru, Hagiwara, Koichi, Hagiwara K Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005 65:7276-82 PubMed ID: 16105816 DOI: 10.1158/0008-5472.CAN-05-0331

13698 Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, Nishimura Y, Funata N, Fukayama M. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes Cancer Sci 2005 96(12):844-57 PubMed ID: 16367903 DOI: 10.1111/j.1349-7006.2005.00121.x

16489 Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S. Proteomic signatures for histological types of lung cancer Proteomics 2005 5(11):2939-48 PubMed ID: 15996008 DOI: 10.1002/pmic.200401166

3338 Seike, Masahiro, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Gemma, Akihiko, Kudoh, Shoji, Hirohashi, Setsuo Proteomic signature of human cancer cells. Proteomics 2004 4:2776-88 PubMed ID: 15352251 DOI: 10.1002/pmic.200300795

13743 Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, Maeshima A, Yamada T, Matsuno Y, Fukayama M, Yokota J, Hirohashi S. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas Am J Pathol 2002 160(3):1129-41 PubMed ID: 11891209 DOI: 10.1016/s0002-9440(10)64933-4

16486 Mase K, Iijima T, Nakamura N, Takeuchi T, Onizuka M, Mitsui T, Noguchi M. Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis Lung Cancer 2002 36(3):271-6 PubMed ID: 12009237 DOI: 10.1016/s0169-5002(02)00004-1

6175 Arai K, Teratani T, Nozawa R, Yamada T. Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol Rep 2001 8(3):591-6 PubMed ID: 11295086 DOI: 10.3892/or.8.3.591

2483 Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000 6:2431-9 PubMed ID: 10873096

1505 Shiraishi M, Chuu YH, Sekiya T. Isolation of DNA fragments associated with methylated CpG islands in human adenocarcinomas of the lung using a methylated DNA binding column and denaturing gradient gel electrophoresis Proc Natl Acad Sci U S A 1999 96(6):2913-8 PubMed ID: 10077611 DOI: 10.1073/pnas.96.6.2913